BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:REGN22530 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of REGN22530\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07675824-11303@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20290914
DTEND;VALUE=DATE:20290915
SUMMARY:REGN22530: Phase 1/2 readout est. (NCT07675824)
DESCRIPTION:REGN22530\, phase 1/2\, Glaucoma.\nStudy: REGN22530 for Adults 
 With Primary Open Angle Glaucoma or Ocular Hypertension\nEstimated primary
  completion: 14 September 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/regn22530#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07675824
URL:https://assetmemo.bio/drug/regn22530#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
